| Article ID | Journal | Published Year | Pages | File Type |
|---|---|---|---|---|
| 10011282 | Journal of the American Academy of Dermatology | 2005 | 5 Pages |
Abstract
Infliximab monotherapy may be an additional therapeutic option for the management of refractory severe AD.
Related Topics
Health Sciences
Medicine and Dentistry
Dermatology
Authors
Arnd MD, Christian MD, Bernhard MD, Gerold MD, Michael MD,